Drug-induced dyskinesia when taking Fluvoxamine

Drug-induced movement disorders (DIMD) are a significant problem in clinical practice, especially in the context of the use of psychotropic drugs. These disorders can significantly worsen the quality of life of patients and lead to additional difficulties in the treatment of the underlying disease. In recent years, there has been a growing interest in this topic, which is associated with an increase in the number of antidepressants and antipsychotics prescribed and an increasing awareness of possible side effects. Fluvoxamine is one of the most common selective serotonin reuptake inhibitor, and its use is associated with the risk of developing adverse phenomena such as dystonia and tremor. This emphasizes the need for careful monitoring of the patient's condition and assessment of the risk/benefit ratio. The relevance of the problem is also reinforced by the fact that DIMD can manifest differently in different patients, requiring an individualized approach in each case. In this regard, it is important to continue research in this area in order to better understand the mechanisms of occurrence and methods of treatment of DIMD. We describe a clinical case of the development of dose-dependent DIMD in a patient with an obsessive-compulsive disorder who took Fluvoxamin at a dose of 225 mg/day. As a treatment of acute motor disorders caused by Fluvoxamin, the use of amantadine sulfate (PK-Merz) is being considered, which has a complex effect on neurotransmitter systems and has been shown to be effective in stopping this undesirable phenomenon. It should be noted that Fluvoxamin may have a beneficial effect in tardive dyskinesia and chorea, but the mechanisms of this effect are still poorly understood.